New Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma : Are We Improving Outcomes?
Abrisqueta, Pau (Universitat Autònoma de Barcelona. Departament de Medicina)

Data:	2024
Resum:	Diffuse large B-cell lymphoma (DLBCL) is the most prevalent subtype of lymphoma, comprising heterogeneous patient subgroups with distinctive biological and clinical characteristics. The R-CHOP combination (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) has been the standard initial treatment, yielding prolonged remissions in over 60% of patients with advanced-stage disease. Several attempts to enhance the outcomes of this regimen over the last two decades have shown limited success. Various novel therapeutic approaches have recently emerged in lymphoma, demonstrating promising results. These include small molecules, novel monoclonal antibodies, antibody-drug conjugates (ADC), bispecific antibodies (BsAbs), and chimeric antigen receptor (CAR) T-cell therapy. This review explores recent advancements in therapeutic strategies for DLBCL and their potential impact on the initial management of DLBCL patients.
Ajuts:	Instituto de Salud Carlos III PI17/00943 Instituto de Salud Carlos III PI22/01204
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Diffuse large B-cell lymphoma ; First-line therapy ; Novel therapies
Publicat a:	Journal of clinical medicine, Vol. 13 (march 2024) , ISSN 2077-0383

DOI: 10.3390/jcm13071929
PMID: 38610693

13 p, 269.9 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats